Top Stories News
Top Stories news
-
News HHS Report Cites Fraud by Drugmakers
An HHS report cites fraud by drug and device makers. -
News Big Pharma Aids India's Drug Sales Growth
The Indian pharma industry saw a 16.5 percent upswing in 2010 sales. The growth was fueled by Big Pharma as much as by domestic drugmakers. -
News Furiex Wins Fast Track Designation from FDA
Furiex Pharmaceuticals' MuDelta program has been granted Fast Track designation by the FDA. -
News Teva Starts Lawsuit Against Astrazeneca Over Seroquel Patent-Report Says
Israel's drug maker Teva Pharmaceutical Industries has launched a lawsuit in London to revoke the European patent for Seroquel, paper reports. -
News Cost to Treat Heart Disease in America to Triple by 2030
The future cost to cure heart disease in the U.S. will triple by 2030, according to the American Heart Association. -
News Supplier Controls Move to Stricter Management
In the past five years, several contaminated pharmaceutical products have led to patient injuries and deaths globally. The emphasis on the linkage between supplier control and risk management will continue to increase. -
News SEC Freezes Assets in Biotech Insider Trading Case
The Securities and Exchange Commission announced it has obtained a court order freezing the bank and brokerage accounts controlled by an individual who made more than $800,000 in illegal profits by trading on inside information tipped to him by an empl... -
News AstraZeneca Remains Confident in the NDA Submission for Ticagrelor
AstraZeneca says it remains confident in the NDA submission for ticagrelor and will continue to work with the FDA to progress towards the completion of the review. -
News CHMP Gives Novartis Positive Recommendation for MS Drug
CHMP recommended that Gilenya 0.5 mg daily could be used as a therapy for patients with highly active relapsing-remitting MS. -
News Perrigo to Buy Generic Drugs Maker
Pharmaceutical manufacturer Perrigo hopes the transaction will add more than $200 million to its annual sales during its first fiscal year. -
News Branded Drugs to Remain 1.3% Growth to 2015
Branded drugs are expected to slow their sales growth to a very low stage due to patent losses. -
News Benefit-risk Review of Multaq Started
The European Commission has requested the Agencys Committee for Medicinal Products for Human Use assess all available data concerning the possible risks of liver injury. -
News Many American Companies Intend to Drop Employee Coverage in 2014 as Health Care Reform Takes Full Effect
Companies in the U.S. are reviewing their options and considering reductions for the employee health care benefits due to the health care reform. -
News All About Thyroids - What You Need to Know
Our body needs to be in balance with its systems under normal functions. One of those major regulatory systems in the body is the Endocrine System. -
News Genzyme To Build New Plant for Pompe Disease Drugs
A new pharmaceutical plant will be built by Genzyme for larger production capacity to satisfy the growing need for Myozyme and Lumizyme. -
News Sanofi-Aventis May Prolong Offer For US Genzyme
Sanofi-Aventis offer for biotech firm Genzyme ends this Friday. The deadline is likely to be extended once again and the offer may see an increase towards USD80 per share. -
News BIA and NZBIO Alliance Formed
Two trade associations representing innovative bioscience companies in the UK and New Zealand have established their alliance to dedicate more to bioscience companies. -
News The 10 Biotech IPOs of 2010
Looking over the top 10 biotech IPOs of 2010, the best performer doesn't actually have a pipeline of therapeutics. But for the year of 2011, investors will have their biotech dreams set on best products. -
News WHO Promotes Rational Use of Medicines
A programme launched in India by WHO aims to promote students' reasonable adoption of medicines. -
News Famar To Acquire Sanofi-Aventis Madrid Plant
Sanofi-Aventis and Famar expands their cooperation as a new agreement has been set for a manufacturing plant in Madrid. -
News Alzheimer's Foundation International Forms Alzheimer's Foundation of Israel
The establishment of the Alzheimer's Foundation of Israel highlights the worldwide attention to Alzheimer's crisis and is an international commitment to deliver better care and treatment for Alzheimer's population in Israel. -
News Genentech Informs Customers Of Important Information About Triad Groups
Due to concerns about potential contamination of the Triad Groups products, Genentech recalls alcohol prep pads. -
News WSJ: Sanofi, Genzyme Working on $80-per-share Deal
Sanofi-Aventis and Genzyme are debating their terms for a transaction which analyst believes has a chance of being reached before before Jan. 21 when Sanofi's current offer expires. -
News People to Actively Manage Their Type 2 Diabetes
A new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk will be launched in America to help people actively manage their disease. -
News Epizyme Lands $650M GSK Deal
GlaxoSmithKline has a partnership deal with Epizyme who will help GSK discover small molecule drugs for enzymes called histone methyltransferases. -
News Merck KGaA Acquires Supplier to Biopharma Industry in China
Merck KGaA has acquired 100% of the share capital of Beijing Skywing Technology Co., Ltd., a leading supplier of cell-culture media products, related technical services and bioreactors in China. -
News Layoffs down, Construction up for 2010 Pharma
2010 was a big year for pharma layoffs, plant closures and other sorts of cutbacks. But some new stats suggest that it wasn't quite as bad as 2009. -
News Pfizer, Santaris Expand RNA Pact
Santaris Pharma and Pfizer have expanded their collaboration for the development and commercialization of RNA-targeted medicines using Santaris Pharmas Locked Nucleic Acid (LNA) drug platform. -
News Cirrhosis Etiology a Major Factor in Cancer Risk
Patients with cirrhosis are at a significantly higher risk of cancer and a new study by U.S. researchers adds to what's already known about those risks. -
News 2010: Another Blah Year at FDA as New Drug Approvals Slip
2010 will not go down in biotech history as a particularly fruitful year for new drug approvals. -
News India Mulls Limits on Foreign Pharma Deals
Spooked by recent buyouts, Indian officials are weighing a new cap on foreign investment in domestic companies. -
News FDA Approves Testosterone Gel Applied to Thigh
The US FDA has approved a clear, odorless testosterone gel that is applied directly to the front and inner thigh. -
News 2010: The R&D revolution-Phase II
If 2009 was the year of the mega-merger, 2010 was the year of continuing R&D reorganization, downsizing and evolution. -
News 2010: Partnering takes on fresh urgency
Chris Viehbacher wasn't playing around when he said that Sanofi-Aventis ($SNY) was going to turn to outside partners for more of its innovative thinking. -
News 2010: The little IPO engines that usually couldn't
Every year everybody who's anybody in biotech--and a lot who aren't--goes to the JP Morgan conference in San Francisco in January. -
News 2010: The FDA gets tougher on safety
Every year brings a new discussion of whether the FDA is getting tougher. This year the question was just how much tougher regulators have become under the Obama administration. -
News Big Pharma still big on emerging markets
The emerging-markets gold rush continues. Drugmakers continued their race into those fast-growing, tantalizing new markets. India, China, Brazil, Russia, Mexico. -
News EHSI: China Emerging as a Stem Cell Leader
Recent breakthroughs show that China is emerging as a world leader in stem-cell research and development, says Emerging Healthcare Solutions President and CEO Cindy Morrissey. -
News Arena maps out its one-year plan for lorcaserin
Arena Pharmaceuticals and its partners at Eisai have had a chance to review exactly what the FDA wants to see on their experimental weight drug. -
News J&J investors fault board for ignoring 'red flags'
Some Johnson & Johnson ($JNJ) investors have resorted to court action, saying that directors and executives not only ignored 'red flags' that something was rotten within J&J, but allowed the company's once-stellar reputation to be destroyed. -
News Novartis aims Gilenya at advanced MS--and $5.4B
Novartis latest product, the multiple sclerosis treatment Gilenya, has already been hailed as a prospective blockbuster. -
News China plans 40% price cuts on key drugs
For the second time in two months, we're seeing reports that Chinese officials are planning to lower drug prices. -
News Novartis to plow $500M into Russia
Novartis' pledged to invest $500 million in Russian manufacturing, R&D and public health. -
News Big Pharma tops defense at government fraud
According to a new report, drugmakers defraud the federal government more than any other business. -
News Roche provides update on Avastin following reviews in Europe and the United States
Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by EMA) and FDA, the following regulatory announcements were made by the individual health authorities. -
News Cardinal Health today announced that the Federal Trade Commission has granted early termination of the waiting period under the
GE Healthcare today announced the expiration of the initial offering period of the previously announced tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc.. -
News Indian pharma draws Chinese industry into trade pact
Indian drugmakers are aiming to team up with China in a bid to outpace western drugmakers who've been scrambling to grab market share in both countries. -
News EMA chief blasts $60B in wasted R&D spending each year
The outgoing chief of the European Medicines Agency concluded that the $85 billion the industry spends on drug R&D each year is simply wasted. -
News Glaxo Set to Re-Start Share Buyback
GlaxoSmithKline is splashing out UKpound162m on a protein drinks maker, but signalled that a lack of cheap takeover deals could see the drugs giant re-start its multi-billion pound share-buyback programme. -
News THE SAGE GROUP Reports that in 2010 Approximately 3 Million People in Western Europe Suffer from Critical Limb Ischemia
A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI). -
News Bayer: 35 million Euros for the expansion of the development of biologicals
Bayer HealthCare is building a new facility center in Wuppertal on an area of some 1,000 square meters for the biotechnological production of pharmaceuticals to be used in clinical trials. -
News 36 Million Americans have Bought Medications Online Without a Doctor's Prescription
Illegal online drug sellers have provided tens of millions of Americans prescription medication via the Internet without a valid prescription, recent research has found. -
News Amgen trial success has analysts talking billions
New data shows that Xgeva (denosumab) delayed the spread of prostate cancer into bone, and that's set the oncology world abuzz. -
News India, EU patch up drug-transit dispute
Negotiators say India will withdraw its complaint filed at the World Trade Organization, now that it has reached an agreement with E.U. trade police. -
News Genzyme Reiterates Board's Position on Sanofi-Aventis Tender Offer
Genzyme Corp. today reiterated the unanimous recommendation of its board of directors. -
News Sanofi expected to extend Genzyme bid
Sanofi-Aventis' ($SNY) lowball bid for Genzyme ($GENZ) is set to expire at midnight tonight. -
News Medical Biotechnology Sector Grows Despite Economic Downturn
The BioIndustry Association welcomes the publication today of the latest government statistics highlighting the growth of the UK's innovative bioscience sector. -
News Russia favors domestic pharma with $3.9B
Russia has been rumbling at global pharma for awhile, but Prime Minister Vladimir Putin has sharpened his warnings to foreign drugmakers. -
News Sanofi almost beats Pfizer at M&A
Pharma M&A is up by 20 percent so far this year as drugmakers scramble to refill depleted pipelines, push into emerging markets and diversify beyond prescription drugs. -
News FDA panel supports approval of Orexigen's obesity drug
In what is likely to prove a shocker for many FDA watchers, the agency's expert advisors voted 13 to 7 in favor of approving Orexigen's obesity drug Contrave. -
News Merck KGaA Donation Program Supports Schistosomiasis Control in Africa
Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis. -
News Bayer's Perspective on Innovation 2010
The Bayer Group aims to invest its resources as a whole more consistently in growth and innovation capability. 'We have a very successful record in innovation,' Management Board Chairman Dr. Marijn Dekkers said. -
News Public believe China and India set to become World leaders for innovation
China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca. -
News Roche, Baylor Research Institute Partner in Human Immunology Research
Focus on cancer vaccines, auto-immune disease diagnostics and treatment -
News Sanofi, Genzyme mull offer adjustments before Dec. 10 deadline
As time runs down on Sanofi-Aventis' $69-per-share offer for Genzyme --the offer expires Dec. 10--both sides are still far apart on an agreement. -
News New J&J recalls spawn worries of FDA action
The steady drumbeat of downbeat manufacturing news and recalls has heightened worries among market-watchers. -
News Genzyme Completes Sale of Genetic Testing Business to LabCorp
Genzyme Corporation has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash. -
News Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
Bristol-Myers Squibb Company and Alvin Ailey American Dance Theater announced the launch of the 2011 REYATAZ? (atazanavir sulfate) 'Fight HIV Your Way' contest. -
News China advances price controls on foreign meds
China is working on a step-by-step reduction in drug prices that previously had been excused from the government's controls. -
News Law and order on the social media frontier
The New England Journal of Medicine is weighing in on social media. -
News Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets
Merck KGaA announced that the U.S. Food and Drug Administration has extended its review period for Cladribine Tablets. -
News FDA Extends Priority Review of Cladribine in Relapsing MS
FDA extended the review to 'provide additional time for a full review of additional information provided under the new drug application.' -
News Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. -
News J&J pulls more children's drugs off store shelves
Johnson & Johnson ($JNJ) execs should write a blues song about recalls. -
News Stelmi to open a technical centre for innovation
Stelmi has created a technical centre at its headquarters near Paris, which will be operational early next year. -
News Honeyman to open pharma training facility
UK-based Honeyman Group will open a pharmaceutical training facility in February 2011. -
News 'Record' drug shortages include cancer meds
The FDA has released its latest list of scarce drugs, and several cancer drugs are included. -
News Privacy groups ask FTC to probe online marketing
Privacy advocates are asking the Federal Trade Commission to investigate how that information is used in drug marketing. -
News Roche dumps hep C development deal with Ligand
Roche is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals, according to the UK biotech. -
News UCLA researcher targeted by animal rights activists
Animal rights activists have claimed responsibility for sending a package of razor blades to a UCLA researcher involved in animal studies. -
News Genzyme Successfully Meets First Milestones of FDA Consent Decree
Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree. -
News Xention raises ?8m to fund drug development
UK biopharmaceutical firm Xention has raised ?8m in private equity funding to advance the development of drugs to treat atrial fibrillation. -
News WTO generics licensing system could prove useful
WHO has said the little-used World Trade Organisation (WTO) licensing system for generic medicines during health emergencies may actually become useful. -
News Roche announces implementation plans for its Operational Excellence Program
Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September. -
News Europeans are Interested in Online Patient Education Programs
Half of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies. -
News UK government appoints life sciences business adviser
Chris Brinsmead, chairman of AstraZeneca Pharmaceuticals UK, has become the UK governments life sciences business adviser. -
News Journal of Clinical Lipidology Accepted for MEDLINE and PubMed by U.S. National Library of Medicine
The National Lipid Association announced the recent acceptance of its journal for indexing in PubMed and MEDLINE by the U.S. National Library of Medicine. -
News J&J, Takeda recall Velcade on particle fears
Johnson & Johnson has been hit with another recall, but this time J&J wasn't the company overseeing production. -
News Roche drops a bomb on the RNAi field
Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany, Nutley, NJ and Madison, WI. -
News GSK: Not interested in Gemzyme deal
Despite rumors, GlaxoSmithKline's senior vice president of medicines discovery and development, says his company isn't considering a bid for Genzyme. -
News Amgen gets coveted cancer OK for denosumab
Approved as an osteoporosis treatment--sold under the brand name Prolia--the drug got the FDA nod for fracture prevention in certain cancer patients. -
News Cargill Announces Patent Application for Zerose Erythritol As an Orally Disintegrating Tablet Excipient
At CPHI Worldwide 2010, Cargill announced a new pharmaceutical patent application for Zerose? erythritol. -
News Paris Pharma Events Smash All Attendance Records
Attendees up by 14%,* Exhibitor Numbers Increase to 1934. -
News Benlysta review spooks investors ahead of FDA panel
Shares of Human Genome Sciences had been trimmed 11 percent as investors fretted over the implications of an FDA staff analysis of its lupus drug Benlysta. -
News FDA Approves New Treatment Option for Late-Stage Breast Cancer
The U.S. FDA approved Halaven to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. -
News Deficit commission eyes Medicare drug rebates
For all the promise of tweaking the healthcare reform law in pharma-friendly ways, there's now a counterweight to those very plans. -
News Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. -
News Roche's Avastin rejected by NICE for colon cancer
Roche has failed to get the cancer drug Avastin on the National Health Service formulary for colorectal-cancer treatment. -
News Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
Bristol-Myers Squibb Foundation launches $100 million initiative targeting America's type 2 diabetes crisis. -
News Nycomed is keeping the pace in third quarter 2010
Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pan... -
News Advaxis Granted a Qualifying Therapeutic Discovery Project Credit Totaling $244,479 for Advaxis' Lead Construct Candidate ADXS11
Advaxis was awarded a Qualifying Therapeutic Discovery Project credit from the Federal Government for ADXS11-001. -
News Novartis teamed up with athletes for doctor marketing
Apparently, Novartis ($NVS) has done just that, using professional athletes as a draw at doctor dinners. -
News China Medicine Reports Third Quarter 2010 Financial Results
China Medicine Corporation today announced financial results for the third quarter ended September 30, 2010. -
News Hamburg aims to defend FDA from budget ax
FDA Commissioner Margaret Hamburg is trying to forestall any talk of cutting her agency's funding. -
News Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
Program to Provide Full Regulatory Support for Clients' Clinical Development Programs Under Experienced Leadership. -
News Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
Sanofi-aventis has sent a letter to Genzyme Corporation requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9. -
News PhRMA spent $25M on friendly lawmakers
PhRMA still has its eyes on healthcare reform.In fact, PhRMA spent some big bucks to back candidates who supported healthcare reform the first time around. -
News KOMBIGLYZE XR tablets approved in the US
The US Food and Drug Administration (FDA) approved KOMBIGLYZE? XR for the treatment of type 2 diabetes in adults. -
News Apricus Bio Awarded Three Qualifying Therapeutic Discovery Project Grants
Apricus Bio will use the proceeds of the grant funds to continue development of PrevOnco?, RayVa? and Femprox?. -
News Allergan plots Botox promo for migraine use
Allergan is gearing up to promote Botox as a migraine-fighter, a newly approved use for the wrinkle-fighting, muscle-relaxing drug. -
News China blesses Sanofi ($SNY) foray into OTC meds
Chinese officials gave the go-ahead to Sanofi-Aventis' ($SNY) joint venture with Hangzhou Minsheng Pharmaceutical Group. -
News Pharma can gain and lose from D.C. power shift
As healthcare and pharma experts are finding that the Washington power shift will present some new challenges. -
News Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
Pfizer Inc. reported financial results for third-quarter 2010. -
News In bombshell, DOJ reverses stance on gene patents
The U.S. Justice Department saying that unmodified DNA should not be patentable. -
News Waksal making big development plans for his new biotech venture
Waksal told that his new biotech company will be bigger and better than ImClone ever was. -
News Lipitor recall shares pallets, Puerto Rico with Tylenol, Glumetza
This time driving a Pfizer recall of the cholesterol-fighting blockbuster Lipitor. -
News Drugmakers rack up $1B in small deals
Drugmakers may be focusing on smaller deals this year, rather than the megamergers of 2009, but those smaller buys do add up. -
News Big Pharma backs tropical disease plan
The World Health Organisation (WHO) says four major medicine companies are backing an initiative to boost the flow of pharmaceuticals fighting lower profile tropical diseases. -
News GSK and Amicus Therapeutics sign exclusive agreement
UK pharmaceutical manufacturer GlaxoSmithKline (GSK) has licensed a treatment for Fabry disease from Amicus Therapeutics. -
News GSK to pay $750M over adulterated drugs
GlaxoSmithKline and its subsidiary SB Pharmco have agreed to pay $750 million to resolve criminal and civil allegations relating to the manufacturing and sale of certain adulterated drugs.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance